(NASDAQ: PAHC) Phibro Animal Health's forecast annual revenue growth rate of 4.37% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 132.8%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.67%.
Phibro Animal Health's revenue in 2025 is $1,399,676,000.On average, 6 Wall Street analysts forecast PAHC's revenue for 2026 to be $60,597,743,960, with the lowest PAHC revenue forecast at $57,800,925,008, and the highest PAHC revenue forecast at $62,908,159,616. On average, 6 Wall Street analysts forecast PAHC's revenue for 2027 to be $62,583,890,752, with the lowest PAHC revenue forecast at $59,381,735,720, and the highest PAHC revenue forecast at $64,813,239,192.
In 2028, PAHC is forecast to generate $64,488,970,328 in revenue, with the lowest revenue forecast at $61,327,348,904 and the highest revenue forecast at $66,758,852,376.